Post COVID-19 fibrosis, an emerging complicationof SARS-CoV-2 infection
- PMID: 33425682
- PMCID: PMC7785952
- DOI: 10.1016/j.idcr.2020.e01041
Post COVID-19 fibrosis, an emerging complicationof SARS-CoV-2 infection
Abstract
SARS-COV-2 has created one of the most massive pandemics in modern history. There is a rapid accumulation of data on its epidemiology, clinical course, diagnosis, management, and complications. One of the sequelae of COVID-19 pneumonia and acute respiratory distress syndrome (ARDS) is pulmonary fibrosis. There is a dearth of accurate data on the prevalence of pulmonary fibrosis post-COVID-19. We report a patient who developed dyspnea secondary to pulmonary fibrosis after successful treatment of COVID-19 pneumonia.
Keywords: ARDS; Acute respiratory distress syndrome; COVID-19; Coronavirus infection 2019; Dyspnea; Pulmonary fibrosis; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2.
© 2020 The Authors.
Conflict of interest statement
This manuscript is original work and has not been submitted or is not under consideration for publication elsewhere. All the authors have reviewed the manuscript and approved it before submission. None of the authors have any conflict of interest from publishing this work.
Figures
References
-
- WHO . 2020. Coronavirus disease (COVID-19) Data as received by WHO from national authorities, as of 27 September 2020, 10 am CEST. Global epidemiological situation.https://www.who.int/docs/default-source/coronaviruse/situation-reports/2... [cited 2020 September 30]; Available from:
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
